Nov 17, 2026  ·  3 min read

Helus says its psychedelic pill beat placebo in a depression trial

A birch architect’s model of a small house

A modified mushroom compound added to an antidepressant did better than a dummy pill, but safety and blinding details are thin.

A psychedelic pill for stubborn depression

On November 16, Helus Pharma said its experimental pill, HLP003, beat a dummy pill in a large late-stage trial. Late-stage means the testing step just before a company asks for approval. HLP003 is a lab-modified form of psilocin, the compound the body makes from psilocybin, the psychedelic in some mushrooms. It is meant to be added to an antidepressant that has not helped enough. The US Food and Drug Administration has not approved it, and a second big trial is still running.

How big the gap was

The trial followed 222 adults with moderate to severe depression. All of them kept taking their usual antidepressant and got psychological support from facilitators, who followed a manual. Some also received HLP003 in two dosing sessions, 21 days apart. The others received a placebo, a dummy pill with no drug in it. Patients had to be able to go without nicotine for up to 8 hours during a dosing session. Sessions were recorded on audio and video.

After six weeks, Helus says, the placebo group's depression score fell by 11.9 points. The drug group's score fell 7.6 points more than that. A clinician fills in that score after an interview. The scale runs from 0 to 60, and higher means worse depression.

That placebo drop is common in depression trials, because believing you are being treated helps. So the gap between the groups is the number to watch. Researchers Michael Hengartner and Martin Plöderl put the smallest change patients would notice at about 3 to 6 points on this scale. So patients would likely notice 7.6, if it holds up.

Does it hold up? Helus calls the effect lasting, and the gain was still there at week 12. The gap shrank only a little, from 7.6 to 7.0 points.

At week 6, 56.3% of the drug group had their score fall by at least half, against 28.2% on placebo. At week 12 those shares were 45.5% and 19.1%. I read that as help for many patients but not all, and for fewer by week 12, though the drug group stayed ahead.

Patients from this trial can join a 43-week follow-up study called EXTEND. It is set up to look at long-term safety, how long the effect lasts and whether repeat doses help. What about the risks?

“I find the result promising, but I want to know how blinding was checked and what the serious events were before I trust it.”

The safety details left out

Helus says most side effects were mild to moderate, short-lived and mostly on dosing day. It also reports three serious events linked to the treatment. All of them happened in the drug group, and Helus says the placebo group had none. Helus does not say what the events were.

On an investor call, executives named one: a suicide attempt by a patient who had not responded to treatment, 55 days after the second dose. Helus also gives no overall rates of side effects and no data on suicidal thoughts. Safety is one gap. The way the trial was blinded is another.

Can a psychedelic trial stay blind?

In a good trial, nobody knows who got the real treatment. That is called double-blind. A psychedelic makes this hard, because people feel it. Feeling the drug does not mean it fails to work. But people who work out they got the drug may expect to improve, and expectation alone can lift scores.

Helus calls the trial double-blind. It does not say how it protected or checked the blinding. The same agency asks psychedelic trials to use questionnaires on blinding and expectations. A review of 86 psychedelic trials found that only eight had checked whether blinding held.

Waiting for a second trial

Psychiatrist Joanna Moncrieff and other critics argue that psychedelic depression research is prone to hype and expectation effects. The figures so far come from the company and have not been checked by independent experts.

A second trial, due in the fourth quarter of 2027, tests a lower dose too. Helus says it aims to file for approval in 2028, but it gives no assurance the schedule will hold. If the lower dose works less well than the higher one, I would take that as one more hint that the pill itself is doing the work. Until then, nobody should stop an antidepressant because of this news.

Nov 17, 2026

  1. Nov 17Anthropic adds text watermarking to four Claude 4 models
  2. Nov 17HHS finalizes HIPAA changes: 15-day record access and health app transfers
  3. Nov 17FBI warns attackers are using the Artex AI hacking tool against companies
  4. Nov 16OpenAI lets its AI helpers complete your purchases
  5. Nov 16Fusion launches an early funding program for defense startups

This is our sketchbook.

Two stoneware cups turned towards each other, as if in conversation

Got a good project?
Let’s work on it together.

Let’s talk →

info@ndot.io · New Jersey · Budapest · Biel